Zilurgisertib Fumarate Patent Expiration

Zilurgisertib Fumarate was first introduced by Mirum Pharmaceuticals Inc in its drug Atebrioz on Sep 25, 2026.


Zilurgisertib Fumarate Patents

Given below is the list of patents protecting Zilurgisertib Fumarate, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

NEW
Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Atebrioz US12466808 Aminopyridine Derivatives And Their Use As Selective Alk-2 Inhibitors May 24, 2039 Mirum
Atebrioz US10710980 Aminopyridine Derivatives And Their Use As Selective Alk-2 Inhibitors Jul 18, 2037 Mirum
Atebrioz US10947218 Aminopyridine Derivatives And Their Use As Selective Alk-2 Inhibitors Jul 18, 2037 Mirum



Zilurgisertib Fumarate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Zilurgisertib Fumarate Generic API Manufacturers

Given below is the list of companies who have filed for Zilurgisertib Fumarate generic, along with the locations of their manufacturing plants worldwide.